arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Agentix Corp.

AGTX
Price unavailable
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
53 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
48
Health
Weak
Neutral
auto_awesome

Analytical Summary

Agentix Corp. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC 1.5%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close.

53-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-77.11K
↑ +57.6%
Operating Margin Operating profit as % of sales
-444.6%
↓ -224.1%
FCF / Share Free cash flow per share
$-0.00
↑ +96.6%
Long-Term Debt Long-term obligations
$110.00K
↑ +29.4%

Health Breakdown

Returns
70
Financial Health
31
Cash Quality
27

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 53 quarters